1. Home
  2. BYD vs COGT Comparison

BYD vs COGT Comparison

Compare BYD & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boyd Gaming Corporation

BYD

Boyd Gaming Corporation

HOLD

Current Price

$82.19

Market Cap

5.9B

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$34.16

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BYD
COGT
Founded
1973
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Hotels/Resorts
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
5.9B
IPO Year
1996
2018

Fundamental Metrics

Financial Performance
Metric
BYD
COGT
Price
$82.19
$34.16
Analyst Decision
Hold
Strong Buy
Analyst Count
11
15
Target Price
$90.82
$36.21
AVG Volume (30 Days)
854.9K
1.5M
Earning Date
04-23-2026
05-06-2026
Dividend Yield
0.93%
N/A
EPS Growth
264.46
N/A
EPS
1.37
N/A
Revenue
$2,626,730,000.00
$7,871,000.00
Revenue This Year
$1.71
N/A
Revenue Next Year
$2.74
$1,733.58
P/E Ratio
$58.93
N/A
Revenue Growth
9.41
N/A
52 Week Low
$72.71
$5.04
52 Week High
$89.96
$43.73

Technical Indicators

Market Signals
Indicator
BYD
COGT
Relative Strength Index (RSI) 49.95 47.39
Support Level $80.76 $33.26
Resistance Level $84.62 $37.69
Average True Range (ATR) 1.85 1.28
MACD -0.01 0.03
Stochastic Oscillator 53.72 64.55

Price Performance

Historical Comparison
BYD
COGT

About BYD Boyd Gaming Corporation

Boyd Gaming Corp is a multi-jurisdictional gaming company. The company operates wholly-owned gaming entertainment properties (casino space, slot machines, table games, and hotel rooms) in Nevada, Illinois, Indiana, Iowa, Kansas, Louisiana, Mississippi, Missouri, Ohio, and Pennsylvania. Geographical regions separate its business segments: Las Vegas Locals, Downtown Las Vegas, Midwest and South, and Online. The Midwest and South hold the key number of entertainment properties and generate the majority of the company's revenue.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: